STAAR Surgical to Report Second Quarter Results on August 10, 2022

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) is set to release its Q2 2022 financial results on August 10, 2022, after market close. The company will host a conference call and webcast the same day at 4:30 p.m. Eastern. This conference will cover financial results and operational updates. STAAR has specialized in ophthalmic surgery for over 40 years, marketing foldable implantable lenses, notably the Visian ICL, with over 2 million units sold worldwide.

Positive

• Announcement of Q2 2022 financial results expected to provide insights into performance.
• Proven market presence with over 2 million Visian ICLs sold in 75+ countries.

Negative

• None.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close.

STAAR will host a conference call and webcast on Wednesday, August 10 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 904311), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 944172) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 2,000,000 Visian® ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005010/en/

Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical release its Q2 2022 financial results?

STAAR Surgical will release its Q2 2022 financial results on August 10, 2022, after market close.

What time is the STAAR Surgical Q2 2022 earnings call?

The STAAR Surgical Q2 2022 earnings call will be held on August 10, 2022, at 4:30 p.m. Eastern.

How can I join the STAAR Surgical Q2 2022 earnings call?

To join the STAAR Surgical Q2 2022 earnings call, dial 844-200-6205 for domestic callers or 929-526-1599 for international callers.

What is the significance of the Visian ICL for STAAR Surgical?

The Visian ICL is a key product for STAAR Surgical, with over 2 million units sold, highlighting its market presence and consumer acceptance.